278 related articles for article (PubMed ID: 36714582)
1. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.
Standing D; Dandawate P; Anant S
Front Endocrinol (Lausanne); 2022; 13():1112987. PubMed ID: 36714582
[TBL] [Abstract][Full Text] [Related]
2. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
4. Hypothalamic Prolactin Regulation of Luteinizing Hormone Secretion in the Female Rat.
Grachev P; Li XF; Goffin V; O'Byrne KT
Endocrinology; 2015 Aug; 156(8):2880-92. PubMed ID: 25993525
[TBL] [Abstract][Full Text] [Related]
5. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
6. Prolactin induces apoptosis of lactotropes in female rodents.
Ferraris J; Zárate S; Jaita G; Boutillon F; Bernadet M; Auffret J; Seilicovich A; Binart N; Goffin V; Pisera D
PLoS One; 2014; 9(5):e97383. PubMed ID: 24859278
[TBL] [Abstract][Full Text] [Related]
7. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
8. A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration.
Li R; Yang Y; Lan H; Wang Y; Ge Z; Liu X; Zhou Y; Zhang W; Xian L; Yuan H
Endocrinology; 2023 Nov; 164(12):. PubMed ID: 37934803
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.
Damiano JS; Wasserman E
Clin Cancer Res; 2013 Apr; 19(7):1644-50. PubMed ID: 23515410
[TBL] [Abstract][Full Text] [Related]
10. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
11. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.
Bole-Feysot C; Goffin V; Edery M; Binart N; Kelly PA
Endocr Rev; 1998 Jun; 19(3):225-68. PubMed ID: 9626554
[TBL] [Abstract][Full Text] [Related]
12. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
Kavarthapu R; Dufau ML
Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
[TBL] [Abstract][Full Text] [Related]
13. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
14. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.
Damiano JS; Rendahl KG; Karim C; Embry MG; Ghoddusi M; Holash J; Fanidi A; Abrams TJ; Abraham JA
Mol Cancer Ther; 2013 Mar; 12(3):295-305. PubMed ID: 23270929
[TBL] [Abstract][Full Text] [Related]
15. Prolactin and its receptor as therapeutic targets in glioblastoma multiforme.
Asad AS; Nicola Candia AJ; Gonzalez N; Zuccato CF; Abt A; Orrillo SJ; Lastra Y; De Simone E; Boutillon F; Goffin V; Seilicovich A; Pisera DA; Ferraris MJ; Candolfi M
Sci Rep; 2019 Dec; 9(1):19578. PubMed ID: 31862900
[TBL] [Abstract][Full Text] [Related]
16. Internalization of prolactin receptor and prolactin in transfected cells does not involve nuclear translocation.
Perrot-Applanat M; Gualillo O; Buteau H; Edery M; Kelly PA
J Cell Sci; 1997 May; 110 ( Pt 9)():1123-32. PubMed ID: 9175708
[TBL] [Abstract][Full Text] [Related]
17. Recent findings on hyperprolactinemia and its pathological implications: a literature review.
Ghoreshi ZA; Akbari H; Sharif-Zak M; Arefinia N; Abbasi-Jorjandi M; Asadikaram G
J Investig Med; 2022 Oct; 70(7):1443-1451. PubMed ID: 35768141
[TBL] [Abstract][Full Text] [Related]
18. From the molecular biology of prolactin and its receptor to the lessons learned from knockout mice models.
Goffin V; Binart N; Clément-Lacroix P; Bouchard B; Bole-Feysot C; Edery M; Lucas BK; Touraine P; Pezet A; Maaskant R; Pichard C; Helloco C; Baran N; Favre H; Bernichtein S; Allamando A; Ormandy C; Kelly PA
Genet Anal; 1999 Nov; 15(3-5):189-201. PubMed ID: 10596761
[TBL] [Abstract][Full Text] [Related]
19. Use of prolactin receptor antagonist to better understand prolactin regulation of pituitary homeostasis.
Ferraris J; Bernichtein S; Pisera D; Goffin V
Neuroendocrinology; 2013; 98(3):171-9. PubMed ID: 23969780
[TBL] [Abstract][Full Text] [Related]
20. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
